Search academic texts

Registration Number

0225U000825, (0122U001311) , R & D reports

Title

Study of changes in the proliferative activity of breast tumors, functional and structural changes in the thyroid gland in response to neoadjuvant chemotherapy in patients with breast cancer with different molecular genetic phenotypes affected by the Chernobyl accident

popup.stage_title

Оцінити молекулярно-генетичні фенотипи раку молочної залози у пацієнтів, які постраждали від аварії на ЧАЕС, структурні і функціональні зміни в щитоподібній залозі у відповідь на проведення неоад’ювантної поліхіміотерапії з метою подальшого використання як біомаркеру її ефективності.

Head

Lytvynenko Oleksandr O., д.мед.н.

Registration Date

20-01-2025

Organization

State Institution "National Research Center for Radiation Medicine, Hematology and Onkology of the National Academy of Medical Sciences of Ukraine"

popup.description1

To study the changes in the proliferative activity of breast tumors and structural and functional changes in the thyroid gland as a result of neoadjuvant chemotherapy in patients with breast cancer with different molecular genetic phenotypes affected by the Chernobyl accident.

popup.description2

96 patients with breast cancer (breast cancer), affected by the accident at the Chernobyl nuclear power plant, who received neoadjuvant polychemotherapy (NAPCT) were examined. A decrease in Ki-67 indicators as a result of NAPCT was noted in 76% of patients, in 15.6% a complete clinical and pathomorphological regression of the tumor was diagnosed, in 3.1% stabilization was noted and in 5.2% an increase in Ki-67 values. Cancer in situ was morphologically diagnosed in 1.04% of patients with elevated Ki-67 levels. In general, 92.7% of patients showed a positive trend towards NAPCT. A decrease in the size of the primary tumor was noted in all patients after NAPCT, even in patients where Ki-67 indicators did not decrease. Prior to NAPCT, criteria T0, Tis, T1 were not diagnosed in any patient. After neoadjuvant therapy, the number of patients with the specified tumor criteria was 45.9%. Before the start of treatment, 97.9% of patients were diagnosed with metastatic lesions of the regional lymph nodes (LN). After NAPCT, the absence of damage to regional blood vessels was confirmed morphologically in 56.2% of patients. 37.5% of patients were diagnosed with a change in the molecular genetic phenotype of the primary tumor towards the most favorable luminal A phenotype. Structural changes in the thyroid gland (thyroid gland) before the start of treatment were diagnosed in 81.2%, functional in 27.1% of women. After the treatment, structural changes in the thyroid gland were diagnosed in 7.3% and functional changes in 5.2% of patients.

Product Description

popup.authors

Antonenko Yurii V.
Demianov Vladyslav O.
Lishсhenko Oleksii P.
Polishсhuk Valentyn V.

popup.nrat_date

2025-01-20